Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denise Pollard-Knight Insider Profile
4 Followers
Denise Pollard-Knight, Director at OncoMed Pharma, holds 709.52K shares in Mereo Biopharma Group Plc (Ticker: MREO), holds 60.23K shares in Elanco Animal Health (Ticker: ELAN), holds 1.17M shares in Albireo Pharma (Ticker: ALBO).
Profitable Transactions
4 out of 8 Profitable Transactions
Average Return
+0.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Denise Pollard-Knight holds in companies
Most Profitable Insider Trade
Stock:
OncoMed Pharma
(OMED)
(OMED)
Rating:Informative Sell
Date:Jul 02, 2014 - Jul 02, 2015
Return:+10.70%
The most profitable trade made by Denise Pollard-Knight
Denise Pollard-Knight's Trading History
OncoMed Pharma
Jan 05, 2015
―
Informative Sell
82.29K
$1.73M
Albireo Pharma
Nov 07, 2016
―
Uninformative Buy
―
$51.45M
Elanco Animal Health
Dec 04, 2023
Director
Uninformative Buy
―
$869.13K
Mereo Biopharma Group Plc
Jun 27, 2024
CEO, Director
Uninformative Sell
463.03K
$2.55M
Idenix Pharma
―
―
―
―
List of latest transactions for each holding click on a transaction to see Denise Pollard-Knight's performance on stock
You May Also Like
Denise Pollard-Knight insider profile FAQ
What is the percentage of profitable transactions made by Denise Pollard-Knight?
The percentage of profitable transactions made by Denise Pollard-Knight is 50%.
What is the average return per transaction made by Denise Pollard-Knight?
The average return per transaction made by Denise Pollard-Knight is 0.40%.
What stocks does Denise Pollard-Knight hold?
Denise Pollard-Knight holds: OMED, ALBO, ELAN, MREO, IDIX stocks.
What was Denise Pollard-Knight’s latest transaction?
Denise Pollard-Knight latest transaction was an Uninformative Sell of $463.03K.
What was Denise Pollard-Knight's most profitable transaction?
Denise Pollard-Knight’s most profitable transaction was an Informative Sell of OMED stock on July 2, 2014. The return on the trade was 10.70%.
What is Denise Pollard-Knight's role in OncoMed Pharma?
Denise Pollard-Knight's role in OncoMed Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.